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Abstract 
 
Objectives 
To perform a post-hoc analysis of in-hospital costs incurred in a randomized controlled trial 
comparing prostatic artery embolization (PAE) and transurethral resection of the prostate 
(TURP). 
 
Patients and Methods 
In-hospital costs arising from PAE and TURP were calculated using detailed expenditure 
reports provided by the hospital accounts department. Total costs including those arising 
from surgical and interventional procedures, consumables, personnel, and accommodation 
were analysed for all of the study participants and compared between PAE and TURP using 
descriptive analysis and two-sided t-tests adjusted for unequal variance within groups 
(Welch t-test).  
 
Results 
Mean total costs per patient (± SD) were higher for TURP at €9,137 ± 3,301 than for PAE at 
€8,185 ± 1,630. The mean difference (md) of €952 was not statistically significant (p=0.07). 
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While the mean procedural costs were significantly higher for PAE (md €623 (p=0.009)), 
costs apart from the procedure were significantly lower for PAE with an md of €1,627 (p< 
0.001). Procedural costs of €1,433 ± 552 for TURP were mainly incurred by anaesthesia, 
whereas €2,590 ± 628 for medical supplies were the main cost factor for PAE.  
 
Conclusions 
Since in-hospital costs are similar but PAE and TURP have different efficacy and safety 
                     ’              d        d  x           – rather than finances – should be 
taken into account when deciding between PAE and TURP.  
 
Key words: Prostatic artery embolization; transurethral resection of the prostate; benign 
prostatic hyperplasia; prostate; obstruction; costs;  
 
Introduction 
Benign prostatic hyperplasia (BPH) affects about 50% of men aged 50–60 years and about 
90% of men aged 85 years or older [1]. Treatment costs of lower urinary tract symptoms 
secondary to BPH (BPH-LUTS) are a substantial economic burden that will increase in the 
future due to demographic changes. Thus, the estimated annual treatment costs were US$ 4 
billion in the United States in 2006, and €858 per patient in Europe in 2003 [2, 3].  
Transurethral resection of the prostate (TURP) is still the gold standard for most patients if 
conservative and medical treatment fail [4]. Although it is performed in more than 100,000 
men annually in the USA [5], it is associated with a high morbidity [6, 7], 40% of patients 
have residual LUTS requiring drug treatment within 5 years after surgery [8], and an 
endourological reintervention rate of 12.3% at 8 years has been reported [9]. These 
drawbacks have led to a continuous search for less invasive alternative treatment options.  
 
Prostatic artery embolization (PAE) is a minimally invasive endovascular procedure 
performed under local anaesthesia and was shown to improve BPH-LUTS for the first time in 
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2000 [10]. The improvement in BPH-LUTS after PAE is similar to that achieved by TURP 
and is associated with fewer adverse events [11-14]. PAE was therefore recently 
recommended as a minimally invasive treatment alternative for BPH-LUTS by the National 
Institute for Health and Care Excellence (NICE) [15]. Desobstructive efficacy with PAE is, 
however, inferior to that associated with TURP [13], and no long-term findings have so far 
been published. Although recent urological guidelines still do not yet recommend PAE 
outside controlled studies [4, 16], it is increasingly being performed worldwide. 
 
Considering the high economic burden of BPH-LUTS treatment and the substantial 
differences between technical aspects of PAE and established transurethral surgical 
treatments, cost analyses in this field seem to be of particular interest. Only one cost 
analysis is available for PAE so far: Bagla et al. [17] retrospectively compared costs of 
patients undergoing PAE or TURP in a hospital setting in the USA, and found statistically 
significantly lower costs for PAE. 
 
Treatment costs strongly depend on the performance setting and may also vary between 
different health care systems, regions, and institutions. The aim of this study, therefore, was 
to analyse costs that occurred in a randomized controlled trial comparing the efficacy and 
safety of PAE and TURP in Switzerland [13].  
 
Patients and Methods 
Study design 
Data were derived from an unblinded, single-centre, randomized, controlled trial [13]. The 
study including the present post-hoc analysis was approved by the local ethics committee 
(EKSG14/004)   d    d d b                           ’                     (14/08). Study 
coordination, data management, and data and safety monitoring were performed by 
independent  x                       ’  C        T           (CTU). The trial was performed 
according to the World Medical Association Declaration of Helsinki [18] and the Guidelines 
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for Good Clinical Practice [19] and was registered at ClinicalTrials.gov (NCT02054013). The 
CTU trial statistician (S.G.) performed the data analyses. 
 
Participants 
Inclusion criteria were: (I) men older than 40 years, (II) TURP indicated, (III) patient 
refractory to medical therapy or not willing to undergo or continue medical treatment, (IV) 
prostate size of 25–80 mL measured by transabdominal ultrasound, (V) International 
Prostate Symptoms Score (IPSS) ≥ 8, (VI) IPSS quality of life (IPSS-QoL) ≥ 3, (VII) Qmax < 
12 mL/s and/or urinary retention, and (VIII) written informed consent [13]. 
Exclusion criteria were: (I) severe atherosclerosis, aneurysmatic changes or severe 
tortuosity in the aortic bifurcation or internal iliac arteries, (II) acontractile detrusor, (III) 
neurogenic lower urinary tract dysfunction, (IV) urethral stenosis, (V) bladder diverticulum, 
(VI) bladder stone, (VII) allergy to intravenous contrast media, (VIII) contraindication for 
magnetic resonance imaging (MRI), (IX) pre-interventionally proven carcinoma of the 
prostate, and (X) renal failure (GFR < 60 mL /min) [13]. 
 
Interventions 
PAE was performed by one experienced interventional radiologist familiar with the procedure 
according to established techniques [12, 20]. After insertion of a 16 F transurethral catheter, 
a unilateral femoral sheath was placed in the right common femoral artery under local 
anaesthesia. Prostatic arterial supply was identified by selective internal iliac arteriography 
with a 5 F angiocatheter (Merit Medical Inc., South Jordan, UT, USA). Catheterization of 
prostatic arteries was performed with 1.9–2.4 F microcatheters (Parkway soft; Asahi Intecc, 
Nagoya, JP; Progreat; Terumo, Tokyo, JP; Direxion; Boston Scientific, Natick, MA, USA). 
Embozene® microspheres (Boston Scientific) were used for embolization. 400 μ  
microspheres were used in patients with visible arterial collaterals to extraprostatic territories 
and without the possibility of occlusion with microcoils. All other patients were embolised 
using 250 μ         es. The microspheres, which are delivered in 20 mL syringes containing 
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2 mL of microspheres and 5 mL of NaCl, were diluted with 2.5 or 3 mL of Visipaque 320 (GE 
Healthcare, Little Chalfont, UK) according to the IFU of the manufacturer. Cone beam CT 
was applied only in difficult cases to identify prostatic arteries or prevent off-target 
embolization [21]. PAE was performed bilaterally if possible. Successful embolization was 
defined as absence of the normal blush of the prostate and complete stasis of flow in the 
prostatic arteries on post embolization angiography. The transurethral catheter was removed 
on the morning after the intervention in patients without indwelling catheter before 
hospitalization. All patients received perioperative antibiotic prophylaxis for 24 hours 
(ciprofloxacin 500mg twice daily).  
 
Monopolar TURP was performed under spinal or general anaesthesia by four board certified 
study physicians using a 24 F resectoscope (Karl Storz Endoskope, Binningen, Switzerland) 
with a standard tungsten wire loop (Karl Storz Endoskope, Binningen, Switzerland) and 
electrolyte-free mannitol-sorbitol solution (Purisole, Fresenius Kabi AG, Bad Homburg, 
Germany).  A 20 F three way catheter was inserted for irrigation after resection, and left for 
at least two days depending on postoperative hematuria. Patients received perioperative 
antibiotic prophylaxis (ciprofloxacin 500 mg twice daily), which was discontinued after 
removal of the bladder catheter or after three days at the latest. 
  
According to the study protocol, the earliest patient discharge after both procedures was to 
be on the second postoperative day. 
 
Financial data 
Detailed expense reports based on work records of activities and services performed by the 
medical and nursing staff, medical consumables used, medications administered, and costs 
for accommodation, rooms, and equipment were provided by the accounts department of the 
hospital for each of the study participants.  These were used to compare in-hospital costs 
arising from PAE and TURP. The calculations of the costs of the interventional and surgical 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
facilities (i.e. technical staff, premises, and equipment) were based on average personnel 
costs per minute, fixed charges for room costs, and proportionate depreciation of equipment. 
For PAE, the costs for operation facilities also included the costs of the imaging studies (e.g. 
angiography, cone beam CT) because they could not be filtered out separately. Fixed 
charges were also applied for the calculation of administrative costs. 
 
Costs were divided into procedural costs and costs arising from the hospital stay.  
Procedural costs for TURP included professional charges of the urologist, costs of operation 
facilities (i.e. technical staff, premises, and equipment), medical supplies required for TURP 
(e.g. resection loop, irrigation solution, tissue evacuation system), costs for anaesthesia (i.e. 
anaesthesiology staff and medical supplies, recovery room) and histological tissue 
examination.  
Procedural costs of PAE included professional charges of the interventional radiologist, 
costs of operation facilities (i.e. technical staff, premises, equipment and imaging studies) 
and medical supplies required for PAE (e.g. local anaesthesia, access sheath, 
microcatheters, guidewires, microspheres).  
 
Costs of the inpatient stay in both groups included physician’  professional charges, 
services by nursing specialists, medical supplies (e.g. irrigation solutions, wound care), 
medication, laboratory services, administration and accommodation (i.e. premises, 
housekeeping, and catering). The latter was based on fixed sums calculated by the accounts 
department.  
 
Expense reports were provided in Swiss francs (CHF) and converted to euros (€)      more 
widely used currency based on the average exchange rate over the study recruitment period 
from 2014 to 2017    €1=1.12 Swiss francs. 
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Statistics 
Cost breakdowns were summarized by means and standard deviations. Differences 
between PAE and TURP were tested using two-sided t-tests adjusted for unequal variance 
within groups (Welch t-test). P-values for recovery variables were also calculated using two-
sided t-tests and those for adverse events using Fisher's exact test. 
 
Results 
A total of 103 patients were randomly assigned to PAE or TURP between February 2014 
and May 2017. Of these, 48 patients underwent PAE and 51 TURP. The data for one patient 
who underwent PAE could not be provided by the accounts department due to incorrect 
allocation by the software. T          ’                w             . Baseline 
characteristics of the study patients and details of how PAE and TURP were performed are 
reported in detail elsewhere [13] and are summarized in Table 1. 
 
Costs for PAE and TURP are categorized in Table 2 and illustrated in Figure 1. Mean total 
costs per patient were lower for PAE (€8,185 SD ± 1,630) compared to TURP (€9,137 ± 
3,301). However, the mean difference (md) of €952 was not significant (p=0.07).   
 
Mean costs for the surgical procedure alone were €4,240 ± 774 for PAE and €3,617 ± 1,429 
for TURP (md €623, p = 0.009). While the main cost factor for the surgical procedure was 
anaesthesia (mean costs €1,433 ± 552) for TURP, medical supplies were the major costs for 
PAE (mean costs €2,590 ± 628).  
 
Mean costs of the inpatient stay were €3,837 ± 1,179 for PAE and €5,405 ± 2280 for TURP 
(md €1,627, p= <0.001). Services provided by the nursing staff were one of the main cost 
factors for the hospital stay for both PAE (€1,265 ± 369) and TURP (€2,143 ± 884). 
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Discussion 
This post-hoc analysis shows that total in-hospital costs tend to be higher for TURP than for 
PAE. The difference between mean total costs was, however, small at 10.4% and not 
statistically significant.  
 
Separate analysis of the costs of the surgical procedure and inpatient costs shows that the 
costs of surgery are statistically significantly higher for PAE, while those for the inpatient stay 
are statistically significantly higher for TURP. Substantial differences were found when the 
costs for the surgical procedure were analysed in more detail. Clear savings were found for 
PAE, as no general or spinal anaesthesia and no recovery room were required. In contrast, 
the procedural costs for PAE were high, especially for medical supplies, the use of 
expensive imaging studies, and a longer intervention time.  
Statistically significantly higher inpatient costs were found for TURP. As TURP is clearly 
more invasive than PAE, a higher degree of postoperative care, including nursing and 
physician services, seem to be plausible.  Moreover, patients had a statistically significantly 
longer hospital stay after TURP.  
 
The randomized study design is the main strength of this study. As PAE and TURP have a 
clearly different safety and efficacy profile, selection bias would have been likely to occur in 
a non-randomized study setting. All financial data used in this analysis were routinely and 
independently assessed by the hospital accounts department. 
However, this study was performed as a post-hoc analysis and therefore has the typical 
limitations of such studies. Patient characteristics and technical variations in PAE and TURP 
were limited due to clear definitions by the study protocol. To assess potential complications, 
the study protocol also defined the minimum hospital stay after surgery, which is an 
important cost factor. PAE can also be performed in an outpatient setting leaving room for 
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considerably lower costs than inpatient treatment. However, considering the frequent 
occurrence of pain in the first 24 hours after PAE [13], also reflected by the more frequent 
use of analgesics in PAE patients in this study, a short term hospital stay seems to be 
justified. In addition, the duration of hospitalization can also be reduced after TURP, as 
shown elsewhere [22, 23]. PAE was performed by a specific interventional radiologist and 
TURP by selected surgeons, which may give rise to expert bias.  
Some of the costs included, e.g. premises and depreciation of equipment, can only be 
estimated. The fixed sums used for the calculations are based on standard calculations used 
by the hospital accounts department. Costs that arose from in-hospital complications (Tab. 
1) could not be filtered out separately by the accounts department of the hospital and, 
therefore, were not available for our analysis. As healthcare systems vary widely between 
different countries, our results will not be generalizable to countries with clearly different 
health care structures.  
 
So far, only one comparative cost analysis has been made available for PAE. Although 
Bagla et al. [17] performed a non-randomized comparison of in-hospital costs for PAE and 
TURP, with statistically significantly different baseline characteristics between the two 
groups, most of their results were in line with our findings. Thus, the authors report on lower 
total costs, and a shorter duration of hospitalization, but higher costs for the intraprocedural 
supplies for PAE. Differences from our study regarding the total amounts might mainly be 
caused by a different assessment and classification of costs, different materials used for 
surgery, and shorter hospitalization times. 
 
Our study focused on in-hospital costs. Postoperative incapacity for work, management of 
post-hospitalization adverse events, and re-interventions and medical treatment for BPH-
LUTS during long-term follow-up would have to be included to estimate the actual economic 
burden for the healthcare system. Such data are not available yet but will be assessed 
during the long-term follow up of the trial. Due to its efficacy and safety profile, PAE has 
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been suggested as an appropriate alternative to medical treatment [13, 24]. In Switzerland, 
costs of €202.05 and €456.25 per year arise from prescription of the cheapest alpha-blocker 
and a combined alpha-blocker and 5-alpha-reductase inhibitor [25]. Considering mean total 
and surgical procedure costs for PAE of €8,185 ± 1,630 and €4,240 ± 774, it seems that not 
only clinical efficacy but also long term cost effectiveness of PAE in this setting still has to be 
demonstrated. 
 
In conclusion, in-hospital costs tend to be higher for TURP than PAE. While consumables 
are clearly more expensive for PAE, it is associated with cost savings regarding anaesthesia 
and post-operative expenses. Considering the rather small cost differences and the different 
efficacy and safety profiles of PAE and TURP, this study clearly suggests that the patient’s 
clinical condition and expectations – rather than treatment costs – are the leading factors in 
determining whether PAE or TURP is chosen. 
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Table and Figure Legends  
Table 1. Baseline characteristics, perioperative data, and recovery parameters of the study 
patients.  
Table 2. Cost breakdown for in-hospital costs arising from PAE and TURP. 
Figure 1. Cost summary for PAE and TURP grouped by mean total (A), procedural (B), and 
inpatient stay (B) costs. (stay: inpatient stay; proc: surgical procedure; suppl: medical 
supplies; facil: operation facilities; phys: physician professional charges; anaest: 
anaesthesia; patho: pathology; lab: laboratory services; medic: medication; accom: 
accommodation; nurs: services by nursing specialists; admin: administrative costs)  
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Table 1. Baseline characteristics, perioperative data, and recovery parameters of the 
study patients.   
Baseline characteristics (mean ± SD) PAE (N = 48) TURP (N = 51) P - value  
Age (years) 65.7 ± 9.3 66.1 ± 9.8  
Body mass index
a 
 26.5 ± 4.2 27.0 ± 3.9  
Charlson Comorbidity Index 3.6 ± 1.6 4.3 ± 2.1  
Prostate specific antigen (PSA) - ng/mL 4.2 ± 5.4 4.5 ± 5.6  
Prostate volume (magnetic resonance imaging) - mL 52.8 ± 32.0 56.5 ± 31.1  
Perioperative data (N and % or mean ± SD) 
Anesthesia    
   General - 26 (51%)  
   Spinal - 25 (49%)  
   Local 48 (100%) -  
Procedure time (min) 122.2 ± 25.8 69.5 ± 22.5 < 0.001 
PAE details (N and % or mean ± SD) 
   Bilateral 
   Unilateral  
36 (75.0%) 
12 (25.0%)  
-  
   Fluoroscopy time (min) 50.8 ± 17.5 -  
   Radiation dose (Gy/cm
2
) 176.5  
± 101.2 
-  
   Use of cone beam CT 5 (10.4%)   
   Pain during intervention (VAS
b
) 0.1 ± 0.6 -  
   Additional analgesics necessary
c
 2 (4.2%) -  
   Amount of embolization particles used (mL) 1.0 ± 0.4 -  
TURP details 
   Time of resection (min) - 58.25 ± 24.33  
   Weight of resected tissue (g) - 25.20 ± 15.16  
Recovery parameters 
Hemoglobin decrease 24h (g/dL) -4.3 ± 7.0 -13.8 ± 11.0 0.001 
Bladder catheter indwelling time (d) 1.3 ± 1.4 3.3 ± 1.4 0.001 
Duration of hospital stay (d) 2.2 ± 0.6 4.2 ± 1.7 0.001 
Adverse events during hospitalization
 
Clavien Grade I 8  (16.7%) 5 (9.8%)               0.38  
Clavien Grade II 0  (0%) 1 (2%)
e
          1.00 
Clavien Grade IIIb  0  (0%) 1 (2%)
f
          1.00 
Values are reported as means ± SD or number (%); All differences in baseline characteristics between groups were 
nonsignificant; p-values for recovery variables are from two-sided t-tests and those for adverse events from Fisher's exact 
test. 
a 
The Body mass index is the weight in kilograms divided by the square of the height in meters; 
b 
VAS: visual analogue scale 
for pain 
c 
Paracetamol 1g was given before surgery 
d 
Postoperative pain was not considered as a deviation from the normal postoperative course; therefore, it was not included 
in the total number of adverse events but assessed separately [13]  
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Table 2. Cost breakdown for in-hospital costs arising from PAE and TURP.  
 
Expense item Mean costs per patient ± SD (€) P-value 
 
 
 
PAE (N=47)
* 
 
 
TURP (N=51) 
 
 
 
Surgical procedure (total)  
 
4,240  
± 774 
3,617  
± 1429 
0.009 
-Physician professional charges  646  
± 460 
538  
± 504 
0.28 
    
-Operation facilities  
(Technical staff, premises, equipment; 
for PAE: imaging studies) 
 
1,005  
± 72 
 
545  
± 280 
< 0.001 
-Medical supplies 
 
2,590 
± 628 
 
717 
± 367 
< 0.001 
-Anesthesia 
(Anesthesiology staff, medical supplies 
needed for anaesthesia, recovery room) 
 
0 1,433 
± 552 
– 
    
-Pathology 
 
0 359 
± 273 
 
– 
Inpatient stay  
(total) 
3,837 
± 1,179 
5,405 
± 2,280 
< 0.001 
-Physician professional charges 
 
1’415 
± 795 
 
1’806 
± 1’043 
0.04 
-Services by nursing specialists 
 
1,265 
± 369 
 
2,143 
± 884 
< 0.001 
-Medical supplies 
 
68 
± 10 
 
120 
± 59 
< 0.001 
-Medication 
 
275 
± 39 
 
147 
± 62 
< 0.001 
-Accommodation 
(Including housekeeping and catering) 
 
528 
± 204 
813 
± 368 
< 0.001 
-Laboratory services 
 
288 
± 130 
 
375 
± 168 
0.005 
-Administrative costs 
 
108 
± 58 
167 
± 158 
0.01 
TOTAL IN-HOSPITAL COSTS 8,185 
±1,630 
9,137 
± 3,301 
0.07 
Costs are reported in euros and values reported are means ± SD; p-values from two-sided t tests. 
* Data from one patient who underwent PAE could not be provided by the accounts department. 
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